Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- Netherlands
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Cancer CA,cancer,cell type cancer,malignancy,malignant Growth,malignant neoplasm,malignant neoplasm (disease),malignant neoplastic disease,malignant tumor,MT,neoplasm (disease), malignant,neoplasm, malignant,organ system cancer,primary cancer,Cancer
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Cachectic Cancer
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- These are cancer patients who lost >5% body weight in the last 6 months.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 76
- Group 1 sample size Number of subjects in the case (exposed) group
- 33
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 3 Months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Wald Test
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure 2B& 3
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: increased abundance in Cachectic Cancer
NCBI | Quality Control | Links |
---|---|---|
Pseudomonadota | ||
Veillonella | ||
unclassified Enterobacteriaceae |
Revision editor(s): Mautin
Signature 2
Source: Figure 2B &3
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: decreased abundance in Cachectic Cancer
NCBI | Quality Control | Links |
---|---|---|
Peptococcus |
Revision editor(s): Mautin
Experiment 2
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-Cachectic Cancer
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Cachetic Cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- 74
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure 2B,3
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: increased abundance in Cachetic Cancer
NCBI | Quality Control | Links |
---|---|---|
Pseudomonadota | ||
Veillonella | ||
unclassified Enterobacteriaceae |
Revision editor(s): Mautin
Signature 2
Source: Figure 2B,3
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: decreased abundance in Cachetic Cancer
NCBI | Quality Control | Links |
---|---|---|
Megamonas | ||
Peptococcus |
Revision editor(s): Mautin
Experiment 3
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Pancreatic carcinoma cancer of pancreas,cancer of the pancreas,carcinoma of exocrine pancreas,carcinoma of pancreas,carcinoma of the pancreas,exocrine cancer,exocrine pancreas carcinoma,exocrine pancreatic carcinoma,pancreas cancer,pancreas carcinoma,pancreatic cancer,pancreatic cancer (not islets),pancreatic carcinoma,pancreatic carcinoma, familial,Pancreatic carcinoma
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy Controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Cachectic Cancer
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- These are Pancreatic cancer patients who lost >5% body weight in the last 6 months analyzed for pancreatic Cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- Not specified
- Group 1 sample size Number of subjects in the case (exposed) group
- 18
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure S3A
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: increased abundance in Cachectic Cancer
NCBI | Quality Control | Links |
---|---|---|
Enterococcus | ||
Lactobacillus | ||
Veillonella | ||
unclassified Enterobacteriaceae |
Revision editor(s): Mautin
Experiment 4
Subjects
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Non-Cachectic Cancer
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- These are Pancreatic cancer patients who did not lost >5% body weight in the last 6 months.
- Group 1 sample size Number of subjects in the case (exposed) group
- 9
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure S3A
Description: Distinct gut microbiota composition in Non-cachectic cancer patients
Abundance in Group 1: increased abundance in Non-Cachectic Cancer
NCBI | Quality Control | Links |
---|---|---|
Enterococcus |
Revision editor(s): Mautin
Experiment 5
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Lung cancer alveolar cell carcinoma,cancer of lung,lung cancer,lung cancer, protection against,lung neoplasm,malignant lung neoplasm,malignant lung tumor,malignant neoplasm of lung,malignant neoplasm of the lung,malignant tumor of lung,malignant tumor of the lung,Nonsmall cell lung cancer,Lung cancer
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Cachectic Cancer
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- These are Lung Cancer patients who lost >5% body weight in the last 6 months.
- Group 1 sample size Number of subjects in the case (exposed) group
- 5
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure S3B
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: increased abundance in Cachectic Cancer
NCBI | Quality Control | Links |
---|---|---|
Enterococcus |
Revision editor(s): Mautin
Experiment 6
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Non-Cachectic Cancer
- Group 0 sample size Number of subjects in the control (unexposed) group
- 19
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure S3B
Description: Distinct gut microbiota composition in cachectic cancer patients
Abundance in Group 1: increased abundance in Cachectic Cancer
NCBI | Quality Control | Links |
---|---|---|
Lactobacillus |
Revision editor(s): Mautin